
Human Apolipoprotein L1 160-168, ALADGVQKV
Description
About Human Apolipoprotein L1 160-168, ALADGVQKV
The Human Apolipoprotein L1 Peptide (IEDB: 161927) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Apolipoprotein Peptide, H-ALADGVQKV-OH (Uniprot: O14791 aa: 160-168) from JPT is produced under strict quality control and quality management.
Human Apolipoprotein L1 160-168, ALADGVQKV - Specifications
- Peptide sequence: H-ALADGVQKV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Breast cancer, Leukemia
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Apolipoprotein L1 160-168, ALADGVQKV
References:
Read References with JPT’s Antigen Peptides
Human Apolipoprotein L1 160-168, ALADGVQKV has been described in:
MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements, nan, 2012 (PMID: Submission)
Two preferentially expressed proteins protect vascular endothelial cells from an attack by peptide-specific CTL., J Immunol, 2012 (PMID: 22544926)
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases., Cell Rep Med, 2021 (PMID: 33521695)
Documentation
Documentation for Human Apolipoprotein L1 160-168, ALADGVQKV
Properties
Properties of Human Apolipoprotein L1 160-168, ALADGVQKV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Breast cancer, Leukemia |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Apolipoprotein |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Apolipoprotein L1 160-168, ALADGVQKV
Information | Values |
---|---|
Sequence: | H-ALADGVQKV-OH |
Specifications: | 9mer peptide as TFA salt |